SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Clinical trials for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a dengue vaccine be safe for autoimmune patients? new trial aims to find out
⭐️ VACCINE ⭐️ Recruiting nowThis study tests whether the Butantan-Dengue vaccine is safe and works well in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable on low or no immune-suppressing drugs. Participants receive one vaccine dose and are monitored f…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:07 UTC
-
New lupus drug tracked in global real-world study
Disease control Recruiting nowThis study follows 200 adults with lupus who are starting anifrolumab for the first time, to see how well it works in everyday clinics. Researchers will measure disease activity, skin symptoms, fatigue, and quality of life over time. The goal is to provide real-world evidence to …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
Lupus trial tests NAD+ booster to tame immune system
Disease control Recruiting nowThis study tests whether a supplement called nicotinamide riboside (NR) can reduce inflammation and improve immune cell function in women with mild-to-moderate lupus. About 78 participants will receive either NR or a placebo for 12 weeks. Researchers will measure changes in immun…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called CHT101 for people with severe lupus that hasn't improved with standard treatments. CHT101 uses specially engineered immune cells (CAR-T cells) to target and destroy certain immune cells that drive lupus. The study will enroll 15…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a One-Time cell treatment tame lupus in young patients?
Disease control Recruiting nowThis study tests a new treatment called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't improved with standard treatments. CART19 uses a patient's own immune cells, modified in a lab to target and calm the overactive immune system causing lupus. The g…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New lupus drug enters early human testing
Disease control Recruiting nowThis early-phase trial is testing a new drug called DB-2304 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to check safety and how the body processes the drug. About 148 participants will receive either DB-2304 or a placebo. This is a first step to see…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Could a One-Time cell infusion tame lupus and other autoimmune diseases?
Disease control Recruiting nowThis early-stage study is testing a new cell therapy called FT819 for people with severe autoimmune diseases like lupus, vasculitis, and scleroderma. The treatment involves giving specially engineered immune cells along with chemotherapy drugs. The main goal is to see if it's saf…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New antibody drug takes aim at autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new drug called SAR448501 (DR-0201) in 62 adults with lupus or rheumatoid arthritis. The drug is a bispecific antibody designed to target the immune system. The main goal is to check safety and find the right dose, not yet to prove it works. Partici…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New pill aims to calm lupus skin flares in major trial
Disease control Recruiting nowThis study tests an experimental pill called enpatoran for people with lupus who have active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can significantly redu…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
CAR t therapy takes on lupus, MS, and more in first human safety trial
Disease control Recruiting nowThis early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Polina Stepensky • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New lupus shot aims to tame flares in phase 2 trial
Disease control Recruiting nowThis phase 2 trial tests a new drug called SG301, given as a shot under the skin, for people with systemic lupus erythematosus (SLE). About 120 participants whose lupus is not well controlled by standard treatments will receive either SG301 or a placebo over several months. The g…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Lupus drug continuation trial offers hope for disease control
Disease control Recruiting nowThis study offers continued treatment with deucravacitinib for people with systemic lupus erythematosus (SLE) or related skin lupus who finished earlier trials. It aims to keep the disease under control by providing ongoing access to the medication. Only 35 participants are being…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Engineered immune cells aim to tame childhood arthritis and lupus
Disease control Recruiting nowThis early-phase trial is testing a new treatment called KN5601, which uses a patient's own immune cells (NK cells) that have been engineered to target and destroy harmful B cells. The goal is to see if it is safe and can help children aged 5 and older with rheumatic diseases lik…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could biologic drugs offer a better way to treat lupus kidney disease?
Disease control Recruiting nowThis phase 2 trial is testing whether biologic drugs (belimumab or telitacicept) can improve kidney outcomes in people with active lupus nephritis better than standard therapy. About 50 participants will be randomly assigned to one of three treatment groups for six months. The go…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Nanjing University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis study tests a new treatment called CD19 CAR T cells for people with severe lupus that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and attack faulty immune cells driving the disease. The trial aims to s…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Immune cell therapy takes on tough autoimmune diseases
Disease control Recruiting nowThis early-stage trial is testing a new treatment called CT1190B CAR-T cell therapy for people with moderate to severe lupus or scleroderma that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and potentially calm the ove…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Engineered immune cells take on tough lupus cases
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-019B for people with refractory systemic lupus erythematosus (SLE), a severe form of lupus that hasn't responded to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) from a healthy donor t…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Hangzhou Qihan Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental cell therapy takes on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage trial is testing a new treatment called YTS109 for people with severe autoimmune diseases like lupus and Sjogren's syndrome that have come back or not responded to standard care. About 18 adults will receive a single infusion of these specially engineered immune …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cell therapy aims to tame tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and how…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cell therapy hopes to tame tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these specially designed cells. The main goal is to check if the treatment is safe, and also t…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Revolutionary In-Body CAR-T therapy targets autoimmune diseases
Disease control Recruiting nowThis early-phase study tests a new treatment called TI-0032-III for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard care. The treatment uses a special injection to create CAR-T cells inside the body, which then target and dest…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Therorna • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New lupus drug YK012 enters human trials – hope for patients?
Disease control Recruiting nowThis study tests a new drug, YK012, in people with moderate to severe systemic lupus erythematosus (SLE). The drug is designed to target certain immune cells. The trial will check for safety, side effects, and early signs that the drug might help control lupus. About 189 adults a…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Experimental cell therapy takes on lupus and muscle disease
Disease control Recruiting nowThis early-stage trial is testing a new treatment called LUCAR-G79D for people with lupus or inflammatory myopathies that haven't responded to standard therapies. The treatment involves giving patients specially engineered immune cells to help control their disease. The study is …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis early-phase study is testing a new type of immunotherapy called universal CAR-T cells in 12 people with moderate to severe lupus that hasn't responded to standard treatments. The cells are designed to target and destroy faulty immune cells driving the disease. The main goals…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Engineered immune cells take on lupus in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called MC-1-50 for adults with severe lupus that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. The main goals are to check…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could a cancer drug tame lupus in kids?
Disease control Recruiting nowThis early trial tests if blinatumomab, a drug used for certain blood cancers, can help children with severe lupus that hasn't improved with other treatments. Six children will receive two short courses of the drug and be monitored for a year. The main goals are to check safety a…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Mao Jianhua • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New lupus drug candidate enters human trials
Disease control Recruiting nowThis study tests an experimental drug called SSGJ-626, an antibody that targets a protein on certain immune cells, in people with systemic lupus erythematosus (SLE). The trial will enroll 198 adults aged 18-70 with SLE. Participants will receive either the drug or a placebo as a …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could a new drug replace steroids for lupus kidney patients?
Disease control Recruiting nowThis Phase 3 trial tests whether a drug called obinutuzumab, combined with mycophenolate mofetil (MMF), can control lupus nephritis without the need for oral steroids. About 196 people with active lupus kidney disease will be randomly assigned to either the obinutuzumab/MMF regim…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called universal CD19/20 CAR-T cells for people with moderate to severe lupus that hasn't improved with standard therapies. The treatment uses specially engineered immune cells to target and potentially reset the faulty immune response…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New lupus drug cizutamig enters early human safety trials
Disease control Recruiting nowThis early-stage study is testing a new drug called cizutamig in about 47 adults with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The main goal is to check if the drug is safe and tolerable, and to see how it moves through the body. Participants must have ac…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Candid Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New 'Smart' immune therapy takes on lupus and arthritis
Disease control Recruiting nowThis early-phase study is testing a new drug called CC312 in 18 adults with severe autoimmune diseases like lupus and rheumatoid arthritis that haven't improved with standard treatments. CC312 is a type of immune therapy designed to target and destroy faulty B cells, similar to C…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 26, 2026 18:43 UTC
-
New drug VIS171 enters human trials for lupus, hair loss, and kidney disease
Disease control Recruiting nowThis early-stage trial tests a new drug called VIS171 in 30 people with lupus, alopecia areata, or a kidney condition called FSGS. The main goal is to check safety and how the body handles the drug. Participants receive VIS171 as a shot under the skin, alongside their usual care,…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:25 UTC
-
Immune reset: CAR-T therapy takes on lupus, myositis, and ITP
Disease control Recruiting nowThis early-phase study tests a new cell therapy called BZE2204 in 20 people with lupus, myositis, or immune thrombocytopenia (ITP) that has not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and calm the overactive immune syste…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: Shanghai Cell Therapy Group Co.,Ltd • Aim: Disease control
Last updated Jun 26, 2026 18:04 UTC
-
Cord blood cells could tame lupus in first human test
Disease control Recruiting nowThis early-phase trial is testing whether a single injection of stem cells from donated umbilical cords is safe for people with active lupus. Ten adults will receive the cells alongside their usual care. Researchers will monitor side effects and check for signs that lupus activit…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: LiveKidney.Bio • Aim: Disease control
Last updated Jun 26, 2026 16:22 UTC
-
Neck scan could predict heart attacks in arthritis patients
Prevention Recruiting nowThis study tests whether using a carotid ultrasound (a neck scan) to find hidden plaque in arteries can help prevent heart attacks and strokes in people with inflammatory rheumatic diseases like rheumatoid arthritis or lupus. About 1,944 participants aged 50 and older will be spl…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: Instituto de Investigación Marqués de Valdecilla • Aim: Prevention
Last updated Jun 27, 2026 12:39 UTC
-
Study links gum health to rare kidney diseases
Knowledge-focused Recruiting nowThis study looks at gum disease in people with rare kidney disorders like Alport syndrome, Fabry disease, and tuberous sclerosis, as well as lupus. Researchers will compare 100 participants to those with chronic kidney disease and healthy controls. They aim to understand how comm…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Stefan Lujinschi • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Lupus drug may harm ovaries – could a hormone shot help?
Knowledge-focused Recruiting nowThis study surveys women under 40 with lupus who are starting cyclophosphamide, a drug that can damage ovaries and cause infertility. Some received an additional drug called GnRHa to protect their ovaries. Researchers will compare menstrual health and fertility between those who …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Lupus patients who failed multiple drugs under observation in new study
Knowledge-focused Recruiting nowThis study is observing 223 people with active lupus (including kidney inflammation) who haven't gotten better with steroids and at least two immunosuppressants. Researchers want to see how well today's standard treatments work for these tough cases. The goal is to measure how ma…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Heart scans aim to spot hidden risks in kids with lupus
Knowledge-focused Recruiting nowThis study looks at 60 children with lupus to find early signs of heart problems using non-invasive ultrasound. The goal is to identify which children are at higher risk for heart issues. No new treatments are being tested.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Massive lupus registry launches to unlock secrets of the disease
Knowledge-focused Recruiting nowThis study is building a large registry and biorepository of 3,500 adults with systemic lupus erythematosus (SLE), including those with lupus nephritis and neuropsychiatric lupus. Participants will provide clinical data and biospecimens over time, creating a resource for future r…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Lupus Research Alliance • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
10,000 lupus patients needed for landmark online study
Knowledge-focused Recruiting nowThis study is a fully online registry for adults and children with lupus. Participants fill out surveys every six months about their symptoms, treatments, and quality of life. The goal is to collect real-world data to improve care and guide future research. No travel or clinic vi…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Lupus Foundation of America • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC